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Abstract
Background: Sporadic fatal insomnia (sFI) and fatal familial insomnia (FFI) are rare human prion diseases.
Case Presentation: We report a case of a 33-year-old female who died of a prion disease for whom the diagnosis
of sFI or FFI was not considered clinically. Following death of this patient, an interview with a close family member
indicated the patient’s illness included a major change in her sleep pattern, corroborating the reported autopsy
diagnosis of sFI. Genetic tests identified no prion protein (PrP) gene mutation, but neuropathological examination
and molecular study showed protease-resistant PrP (PrP
res) in several brain regions and severe atrophy of the
anterior-ventral and medial-dorsal thalamic nuclei similar to that described in FFI.
Conclusions: In patients with suspected prion disease, a characteristic change in sleep pattern can be an
important clinical clue for identifying sFI or FFI; polysomnography (PSG), genetic analysis, and nuclear imaging may
aid in diagnosis.
Background
Human prion diseases are rare, transmissible, invariably
fatal neurodegenerative diseases that are characterized
by the accumulation of a misfolded host protein, the
prion protein, in brain tissue. They are classified into
three main groups: sporadic, acquired, and genetic.
Sporadic cases, with no known environmental source of
infection, include sporadic Creutzfeldt - Jakob disease
(CJD), the most common human prion disease, and
sporadic fatal insomnia (sFI), one of the least common
[1]. Acquired cases include iatrogenic CJD, acquired by
medical or surgical procedures, and variant CJD, usually
acquired from consuming beef products contaminated
with the agent of bovine spongiform encephalopathy [1].
Genetic or familial cases are linked to a mutation on the
prion protein gene, and include several subtypes of
Gerstmann Sträussler Scheinker syndrome, familial CJD,
and fatal familial insomnia (FFI) [2]. sFI shares a very
similar phenotype to FFI, but is not associated with a
mutation in the prion protein gene [3]. FFI is linked to
the presence of a D (aspartic acid) to N (asparagine)
variation at codon 178 (D178N) coupled with the
methionine at codon 129 (129M) on the mutant allele
of the prion protein gene (PRNP) [4]. The presence of
valine at codon 129 (129V) coupled with the same
D178N mutation is associated with a very different phe-
notype reminiscent of CJD [4]. sFI lacks the D178N
PRNP mutation but appears to be invariably associated
with methionine homozygosity at codon 129 of the
PRNP, suggesting that 129M, either coupled with the
D178N mutation or present in both alleles in the
absence of the mutation is a requirement for the pheno-
typic expression of fatal insomnia [4].
Although Kawasaki and colleagues described a prob-
able case of sFI in 1997, the disease was definitively
established in 1999 by both Mastrianni et al and Parchi
et al utilizing the term sporadic fatal insomnia [3,5,6].
Parchi and colleagues reported five such cases in sub-
jects between the ages of 36 and 70 years (mean 50)
with duration of illness ranging from 15 to 24 months
(mean 17.8) [3]. An additional ten patients have been
reported in the literature as sFI, expanding the age
range to 30-74 and the disease duration to 13-73
months [6-13].
Like FFI, sFI is characterized pathologically by thala-
mic atrophy and clinically by disrupted sleep, autonomic
dysfunction, and motor abnormalities including myoclo-
nus, ataxia, dysarthria, dysphagia, and pyramidal signs
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that can be mistaken for psychotic signs. Because the
patients are deprived of sleep they may display drowsi-
ness during the day which may be described as hyper-
somnolence unless the abnormal nocturnal sleep pattern
is recognized by electroencephalogram (EEG) and/or
polysomnography (PSG). The rarity of the disease can
make the diagnosis of sFI challenging. To make clini-
cians more aware of an unusual presentation of prion
disease and to demonstrate the importance of pursuing
a thorough sleep history when prion disease is being
considered, we describe the clinical and pathological
details of a patient whose sFI diagnosis had not been
considered antemortem.
Case presentation
Clinical findings
In February 2007, the Centers for Disease Control and
Prevention (CDC) and the National Prion Disease
Pathology Surveillance Center (NPDPSC) notified the
Texas Department of State Health Services (DSHS) of a
32-year-old woman with an 18-month history of pro-
gressive neurological symptoms suggestive of CJD.
(Table 1) Based on the medical record and her neurolo-
gist, her illness began in August 2005 with attention def-
icits and progressive memory loss. In June 2006, she
demonstrated anisocoria and bizarre behavior, including
talking incoherently to herself, and she was then
referred to psychiatry. On a mini-mental state examina-
tion, she scored abnormally low in the measure of atten-
tion and calculation and she had reduced ability to
repeat the names of three unrelated objects [14]. Later
in 2006 she was described as being in constant motion,
h a v i n gu n f o c u s e dh a n dg e s t u r e s ,a n dc o n t i n u e dd i f f i -
culty with ambulation. She was reported as alert, but
confused, sad, and having difficulty with her thought
process. Physicians caring for the case patient discussed
the possibility of several diagnoses such as viral ence-
phalopathy, paranoid schizophrenia, and subacute scler-
osing panencephalitis, yet the overall etiology remained
unclear. By February 2007, the patient was unable to
ambulate and became bed-bound. She continued to
demonstrate bizarre behavior, inability to follow com-
mands, and unintelligible speech. The patient expired in
June 2007, 22 months after the onset of illness.
Over the course of her illness, she had EEGs, magnetic
resonance imaging (MRI) studies, and cerebrospinal
fluid (CSF) tests. The EEG study performed in July 2006
showed generalized slowing with bilateral periodic later-
alized epileptiform discharges. A second EEG performed
two to three weeks later was unsuccessful due to exces-
sive movements of the patient. In April 2006, an MRI
study was negative for intracranial abnormalities.
Another MRI study was completed in February 2007
and it showed supratentorial parenchymal atrophy with
no other acute intracranial findings. CSF studies per-
formed in March 2007 were normal, including the
amount of the 14-3-3 protein determined.
Because of the age of the patient and the potential for
variant or iatrogenic CJD, in July 2007 an investigator
from the DSHS (KMM) interviewed a family member to
obtain additional information about the patient’st r a v e l
history, past medical history, and the symptoms of the
Table 1 Progression of clinical signs and symptoms
Date Clinical signs and symptoms
August 2005 Onset: age 31†
Increased attention deficit†
Progressive memory loss†
Sleep disturbance‡
February
2006
Bizarre behavior‡
Sitting in chair making loud incoherent noises‡
April 2006 MRI - negative for intracranial abnormalities†
June 2006 Anisocoria†
Increased agitation‡
Incoherent speech‡
Balance and gait difficulties‡
Talking to self†
Referred to psychiatry†
Decreased attention, registration and calculation†
July 2006 Electroencephalogram (EEG) - bilateral periodic
epileptiform discharges†
August 2006 Flat affect†
Continued decrease in attention, registration and
calculation†
October
2006
Confused†
Constant movement†
November
2006
Sleep enhancing medication prescribed‡
Unfocused hand gestures†
Continued difficulty with gait†
January
2007
Akathisia -inner restlessness†
Places arms and legs in sustained postures†
Bizarre behavior†
February
2007
Bed-bound†
Unable to ambulate†
MRI - supratentorial parenchymal atrophy with no other
acute intracranial findings†
March 2007 Cerebrospinal Fluid (CSF) 14-3-3 testing performed -
result is not elevated†
Awake most of the time‡
June 2007 Death: Age 33
Duration of illness: 22 months
Autopsied tissue sent to National Prion Disease
Pathology Surveillance Center
August 2007 Western blot revealed presence of abnormal protease
resistant prion protein
Immunohistochemical analysis revealed granular deposits
as seen in prion disease
MM2 sCJD, thalamic type consistent with “sFI”
† Information obtained from medical record
‡ Information obtained from family member
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side the continental United States to Puerto Rico during
1995-96 where she had lived approximately one year.
Her surgical history included two back surgeries for
internal disc disruption and degenerative disc disease.
An anterior lumbar discectomy with interbody fusion at
L4-5 was performed in November 2000 utilizing cadaver
donated bone and in August 2001 another fusion was
performed at L5-S1 utilizing autologous bone. The
donor of cadaver bone was pre-screened minimizing the
possibility of iatrogenic transmission. There was no
familial history of progressive neurological disease or
dementia-like illness. The family member also confirmed
the clinical history including the onset in August 2005
of progressive memory loss and, in February 2006,
bizarre behavior that included the patient’s sitting in a
chair for hours making noises that progressively got
louder.
Following preliminary autopsy results, the NPDPSC
requested the DSHS re-interview the family to ask speci-
fically about the patient’s pattern of sleep. When ques-
tioned about insomnia, the family member recalled that
the patient had experienced disturbed sleep at the time
of her disease onset. The family member also reported
that the patient’s sleep pattern progressively deteriorated
throughout her illness. Some nights, for example, the
patient did not sleep. On other nights when she did
appear to be sleeping, her sleep was intermittent. During
nights that the patient did not sleep, she would roam
the house at all hours, unable to calm down. By August
of 2006, four hours was the maximum amount of sleep
the patient would get in one stretch and at times she
would go two to three days without sleep. Medications
were prescribed to help her sleep but they were not
beneficial.
Genetic analysis
Sequencing of the PrP gene open reading frame revealed
methionine homozygosity at codon 129, with no patho-
genic mutation.
Histological examination
The mediodorsal and pulvinar thalamic nuclei along
with the inferior olives showed severe neuronal loss and
astrogliosis but no spongiform degeneration (SD) (Fig-
ure 1A-D and Figure 2). Astrogliosis with possible neu-
ronal loss and superficial non-specific spongiosis
affected particularly the frontal cortices while typical
fine SD was present in other cortical regions, including
parietal and temporal cortex (Figure 1E and 1F). With
the exception of the presence of some SD in the mole-
cular layer of the hippocampal formation, the hippocam-
pus, basal ganglia, and cerebellum were much less
affected than the cerebral cortex. Torpedoes, fusiform
swellings of the Purkinje cell axons, were detectable in
the granule cell layer of the cerebellum. Except in the
hippocampus, where only the molecular layer was even
weakly stained, immunohistochemical evaluation for the
prion protein (PrP) in the cerebral cortex demonstrated
intense staining in a predominantly ‘synaptic’ pattern
with occasional small clusters of coarse granules (Figure
1G). Meanwhile, the basal ganglia, thalamus, and cere-
bellum were just faintly stained.
Molecular study
High resolution and standard Western blot analyses of
the abnormal and Protease K (PK)-resistant PrP (PrP
res)
from 19 brain regions invariably disclosed the presence
of PrP
res type 2, which, however, varied in amount
according to the location (Figure 3A). Of the two main
types of unglycosylated misfolded prion protein fractions
used as biochemical surrogate markers in prion diseases,
PrP
res type 2 protein is slightly lighter than the PrP
res
type 1 as demonstrated by their electrophoretic mobility
on Western blots. The highest concentration of PrP
res
was observed in most cerebral cortical regions such as
frontal, temporal (including entorhinal), and occipital
cortices, but it was minimal in the hippocampus. Varia-
tions in amount were also detected within the same cor-
tical region (i.e. superior, middle, and inferior frontal
gyri: data not shown). Minimal amounts of PrP
res were
demonstrated in the caudate nucleus and in the three
thalamic nuclei examined: anterior ventral, mediodorsal,
and pulvinar (Figure 3A). No PrP
res was detected in the
cerebellum (Figure 3A). Detectability of PrP
res in the
thalamic nuclei was enhanced either by increasing the
concentration of the antibody 3F4 ten-fold or by preci-
pitating PrP
res with sodium phosphotungstate. (Figure
3B and data not shown). The ratios of the three PrP
res
glycoforms, (diglycosylated, monoglycosylated, and
unglycosylated) in the cerebral cortex and in the pulvi-
n a r ,t h eo n l yt h a l a m i cn u c l e u sw h e r eP r P
res could be
assessed accurately, were 15:42:43 and 28:38:34
respectively.
Discussion and conclusions
The clinical diagnosis of prion disease in patients with
signs of neurodegenerative diseases can be aided by pay-
ing particular attention to aspects of the patient history,
including the patient’s travels, past surgery, neurodegen-
erative illnesses in the family, and to possible changes in
the patient’s sleep pattern. Ancillary tests for suspected
prion disease often include an EEG, MRI, and the mea-
surement of CSF 14-3-3 protein, but these tests are typi-
cally unrevealing in cases of sFI. They also include
genetic testing to detect possible PRNP mutations and
to determine the genotype at codon 129 of the PRNP.
Either valine or methionine can normally occur at the
Moody et al. BMC Neurology 2011, 11:136
http://www.biomedcentral.com/1471-2377/11/136
Page 3 of 8codon 129 of the PRNP and this polymorphism can
strongly influence many aspects of human prion disease,
including the disease phenotype and the susceptibility of
a host to a prion infection. If FI is a diagnostic consid-
eration, potentially helpful additional tests include PSG
and nuclear imaging to demonstrate reduced tracer
uptake in the thalamus [15,16]. Finally, pathological
examination of brain tissue at autopsy is the definitive
way to confirm the presence and type of prion disease.
For the patient described in this report, her long dura-
tion of illness and young age at onset are unusual for
the most common subtype of prion disease, sporadic
CJD [17]. Other forms of CJD were considered but
determined to be extremely unlikely. Although this
young patient showed signs of psychiatric illness at the
beginning of her disease consistent with variant CJD
(vCJD), these signs did not precede her noticeable defi-
cits in attention and memory and she had not traveled
to any country where transmission of vCJD was known
to occur.
Iatrogenic CJD has been associated with a number of
medical procedures. However, it is not known to be
linked with receipt of a bone transplant. Furthermore,
the donor of the bone transplant received by our patient
had been pre-screened providing greater assurance of
the absence in the donor of an infectious or neurological
illness [18]. This patient also had no family history of
neurodegenerative illness.
The history of insomnia was not in the medical chart
nor was a sleep study or nuclear imaging study per-
formed [7]. The neuropathological studies of the brain
tissue demonstrated atrophy of the patient’st h a l a m u s ,
the neuropathological signature of both FFI and sFI,
which then prompted the interview with a family mem-
ber about the patient’s sleep patterns. The diagnosis of
sFI was made at autopsy based on the pathological
Figure 1 Histology and immunohistochemistry. A: Severe neuronal loss and astrogliosis of the mediodorsal thalamic nucleus in the present
case. Neurons are indicated by arrows, reactive astrocytes by circles. B: For comparison, the same thalamic nucleus is shown in an age-matched
subject without prion disease; neurons are indicated by arrows. C: Immunohistochemistry for glial fibrillary acidic protein (GFAP) reveals reactive
astrocytic gliosis in the mediodorsal thalamic nucleus of the present case but not in a control subject of the same age without prion disease (D).
E: Prominent astrogliosis in the frontal cortex. The inset (lower left corner) depicts three reactive astrocytes at higher magnification. F: Fine
spongiform degeneration of the parietal cortex. G: Intense punctate or “synaptic” PrP immunostaining and sparse clusters of small granules in
the cerebral cortex (parahippocampal gyrus; 3F4 antibody).
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the absence of a PRNP mutation. The history of pro-
gressively worsening insomnia is characteristic of sFI
and underscores the importance of taking a careful his-
tory of possible changes in the patient’s sleep pattern
when evaluating an illness suggestive of a prion disease,
particularly if the illness exceeds 12 months in duration.
The consistency of the association of sleep-wake dis-
turbances with FFI and sFI has been recently challenged.
Zarranz et al have examined the sleep disorder in 23
symptomatic carriers of the D178N mutation both
homozygous for methionine (D178N-129MM) and
methionine/valine heterozygous (D178N-129MV) [19].
Eleven of these patients were reported not to have
insomnia. However, only two of these patients had a
PSG study that is essential to rule out the presence of
insomnia often difficult to detect clinically especially in
the D178N-129MV patients. In both these patients PSG
examination did reveal a severe sleep disorder compati-
ble with FFI. The authors also claim that the clinico-
pathological phenotype was that of CJD rather than FFI
in eleven of these 23 patients. However, autopsy exami-
nation of the brain essential to exclude the thalamic
atrophy characteristic of FFI was carried out in only
four of these eleven subjects and the histology of the
thalamus is not described.
Combined, the studies of Landolt et al, Taratuto et al
and La Morgia et al raise the issue of a wider prevalence
of sleep disorder in prion diseases that deserves further
study [20-22]. Landolt et al reported the presence of
sleep-wake symptoms in all of seven patients with pro-
ven sCJD. However, the histology of the thalamus was
examined in only four of the seven subjects and in a
semi-quantitative fashion which regrettably did not
include the assessment of the neuronal loss and the
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Figure 3 Western blot analysis. A: The unglycosylated fraction of PrP
res shows a gel mobility of approximately 19 kDa matching PrP
res type 2
in each brain region examined. S1 (μl): volume of brain supernatant (see Methods) loaded into the gel; T1: PrP
res type 1 (20 kDa) from a case of
sCJD with genotype 129MM used as control. B: Western blot showing PrP
res from the thalamic nuclei indicated after probing with the 1:4,000
concentration of 3F4 compared to 1:40,000 in A. Fc: frontal cortex; Pc: parietal cortex; Tc: temporal cortex; Oc: occipital cortex; Hi: hippocampus;
Ec: entorhinal cortex; Cn: caudate nucleus; Av: anterior ventral thalamic nucleus; Dm: mediodorsal thalamic nucleus; Plv: thalamic pulvinar; Ce:
cerebellum.
100 μm 
Figure 2 Hematoxylin-eosin staining of the mediodorsal
thalamic nucleus. As seen in the present case, the hematoxylin-
eosin staining of the mediodorsal thalamic nucleus also shows
severe neuronal loss in a fatal familial insomnia (FFI) control case.
The arrow indicates a thalamic neuron.
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controls of degree of thalamic atrophy. Furthermore,
impairment of the autonomic system, a prominent com-
ponent of the FFI phenotype, was not investigated in
these cases [20]. These considerations are relevant also
to the report of Taratuto et al of the presence of sleep
impairment similar to that of FFI in a subject with the
E200K-129MM mutation [21]. However, in this case the
thalamus was fairly severely involved with gliosis and
neuronal loss. Finally, La Morgia et al observed a sleep
disorder similar to that of FFI and sFI in a case of
sCJDVV2 with severe thalamic involvement by H-MR
spectroscopy and detectable neuronal loss at histological
examination [22].
Compared to the previous reports of sFI, the present
case shows at least four major similarities: i) the pre-
s e n c eo ft y p e2P r P
res; ii) greater amount of PrP
res in
the cerebral cortex compared to that in the sub corti-
cal regions [3,10]; iii) glycoform ratios in the cerebral
cortex and pulvinar that differ from that reported in
FFI; and iv) no detectable PrP
res in the cerebellum.
These findings along with the prominent thalamic
atrophy and clinical evidence of sleep impairment defi-
nitely justify the classification of the present case as
sFI.
Recently a case of alleged sFI has been reported show-
ing the presence of PrP
res type 1 (rather than type 2 as
in the present and other cases of sFI); the largest
amount of PrP
res in the mediodorsal thalamic nucleus,
and a glycoform ratio characterized by the relative pre-
valence of the diglycosylated PrP
res isoform similar to
that of FFI [23]. If confirmed, this case indicates that, as
in sCJD in general, occasional and unexplained phenoty-
p i cv a r i a t i o n sh a v et ob ee x p e c t e di ns F I .F i n a l l y ,t h e
severe neuronal loss of the anterior ventral and medio-
dorsal thalamic nuclei which contained relatively low
amounts of PrP
res raises the issue of whether other iso-
forms of neurotoxic PrP such as protease-sensitive PrP
are present in the thalamic nuclei in sFI.
Materials and methods
Reagents and antibodies
Proteinase K (PK), sodium phosphotungstic acid
(NaPTA), N-Lauroylsarcosine sodium salt (sarkosyl),
and phenylmethylsulfonyl fluoride (PMSF) were pur-
chased from Sigma Chemical Co. (St. Louis, MO, USA).
Benzonase nuclease was purchased from Novagen
(Gibbstown, NJ, USA). Reagents for enhanced chemilu-
minescence (ECL plus) and the horseradish peroxidase-
conjugated antibody were produced by Amersham Bios-
ciences (Piscataway, NJ, USA). The 3F4 monoclonal
antibody (mAb) was used against PrP residues 106-110
[24].
Brain samples
Human brain tissues were obtained at autopsy and
stored at -80°C. Samples were taken from 19 different
brain regions: superior, middle, and inferior gyri of the
frontal and temporal cortices, the middle gyrus of the
parietal cortex, visual and non-visual occipital cortices,
entorhinal and hippocampal cortices, basal ganglia (cau-
date nucleus, putamen, globus pallidus), substantia
nigra, thalamus (anterior ventral, mediodorsal and pulvi-
nar nuclei), and cerebellum (hemispheres).
Molecular genetics
DNA was extracted from frozen brain tissues in all the
cases, and genotypic analysis of PRNP coding region was
performed as described [25].
Histopathology and PrP immunohistochemistry
Histopathology and PrP immunohistochemistry were
performed as described [26]. The sections were deparaf-
finized, rehydrated, and immersed in TBS-T. Endogen-
ous peroxidase was blocked by Envision Flex Peroxidase
Blocking Reagent (Dako) for ten minutes and washed.
For 3F4 immunostaining only, sections were completely
immersed in 1.5 mmol/L hydrochloric acid and micro-
waved for fifteen minutes. The slides were either incu-
bated with GFAP 1:12000 (Sigma-Aldrich, St. Louis,
MO) or 3F4 1:750 for one hour, washed, and incubated
with Envision Flex/HRP polymer for 30 minutes (Dako).
Envision Flex DAB (Dako) was used to visualize the
immunoreactivity.
Preparation of tissue homogenates and proteinase K
digestion
Brain homogenates (10% w/v) were prepared in lysis
buffer with 100 mM TRIS-HCl (100 mM NaCl, 10 mM
EDTA, 0.5% NP-40, 0.5% sodium deoxycholate, 100 mM
Tris-HCl, pH 8.0) and centrifuged at 1000 × g for five
minutes to collect the supernatant (S1). Homogenates
were incubated with 5 Unit/ml (U/ml) PK [48 Units/mg
specific activity at 37°C, with 1 U/ml equal to 20.8 μg/
ml PK] at 37°C for one hour, and then stopped by the
addition of 2 mM PMSF. Samples were mixed in an
equal volume of 2 × sample buffer (6% SDS, 5% b-mer-
captoethanol, 20% glycerol, 4 mM EDTA, 125 mM Tris-
HCl, pH 6.8) and boiled for ten minutes.
Enrichment of PrP by sodium phosphotungstate (NaPTA)
precipitation
Precipitation of PrP aggregates by NaPTA was con-
ducted as described with minor modification [27].
Briefly, 10% (w/v) homogenates from brain were pre-
pared in PBS lacking Ca
2+ and Mg
2+. The samples were
centrifuged at 1000 × g for 10 minutes at 4°C and
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volume of 4% (w/v) sarkosyl prepared in PBS, pH 7.4,
and incubated for 10 minutes at 37°C. Each sample was
adjusted to final concentrations of 50 U/ml benzonase
and 1 mmol/L MgCl2 and incubated for 30 minutes at
37°C. Aliquots were adjusted with 81.3 μlo fas t o c k
solution containing 4% (w/v) NaPTA and 170 mmol/L
MgCl2 at a final concentration of 0.3% (w/v) NaPTA.
Samples were incubated at 37°C for 30 minutes before
centrifugation at 16,000 × g for 30 minutes. After isola-
tion of the supernatant, the pellet was resuspended in
0.1% sarkosyl prepared in PBS, pH 7.4 for Western
blotting.
Western blotting
Proteins were separated by both non-commercial, home-
made 15% Tris-HCl, 20 cm-long SDS-PAGE gels and
15% Tris-HCl Criterion precast gels (Bio-Rad, Hercules,
CA). Proteins were then transferred to PVDF membrane
(Immobilon-P; Millipore) for two hours at 60 V. The
3F4 antibody was incubated for two hours at room tem-
perature (1:40,000 and 1:4,000). After incubation with
horseradish peroxidase-conjugated sheep anti-mouse
IgG at 1:3000, the PrP bands were visualized on Kodak
film (Eastman- Kodak, Rochester, NY) by the ECL Plus
(GE Healthcare, Fairfield, CT) as described by the man-
ufacturer. Densitometric analysis was performed with
UN-SCAN-IT gel 5.1.
Consent
Written informed consent was obtained from the
patient’s next of kin for publication of this case report.
A copy of the written consent is available for review by
the Editor-In-Chief of this journal.
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